UPDATE: Wedbush Maintains Sequenom at Neutral on Complicated Competitive Environment

In a report published Tuesday, Wedbush maintained Sequenom (NASDAQ: SQNM ) at Neutral with a $5.00 price target. Wedbush reported that, “We are expecting SQNM to report revenue of $33 MM and an EPS loss of ($0.22) when the company reports 4Q12 results after the market closes on Thursday, March